[go: up one dir, main page]

MXPA02011563A - Composicionesy metodos para la terapia y diagnostico de cancer de seno. - Google Patents

Composicionesy metodos para la terapia y diagnostico de cancer de seno.

Info

Publication number
MXPA02011563A
MXPA02011563A MXPA02011563A MXPA02011563A MXPA02011563A MX PA02011563 A MXPA02011563 A MX PA02011563A MX PA02011563 A MXPA02011563 A MX PA02011563A MX PA02011563 A MXPA02011563 A MX PA02011563A MX PA02011563 A MXPA02011563 A MX PA02011563A
Authority
MX
Mexico
Prior art keywords
compositions
diagnosis
cancer
therapy
methods
Prior art date
Application number
MXPA02011563A
Other languages
English (en)
Inventor
Tony N Frudakis
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/699,295 external-priority patent/US6828431B1/en
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of MXPA02011563A publication Critical patent/MXPA02011563A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Se describen composiciones y metodos para la terapia y diagnostico del cancer, particularmente, el cancer de seno. Las composiciones ilustrativas comprenden uno o mas polipeptidos del tumor de seno, porciones inmunogenicas del mismo, polinucleotidos que codifican dichos polipeptidos, y celulas T que son específicas para las celulas que expresan dichos polipeptidos. Las composiciones descritas son utiles, por ejemplo, en el diagnostico, prevencion y/o tratamiento de enfermedades, particularmente el cancer de seno.
MXPA02011563A 2000-05-24 2001-05-22 Composicionesy metodos para la terapia y diagnostico de cancer de seno. MXPA02011563A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US57750500A 2000-05-24 2000-05-24
US59058300A 2000-06-08 2000-06-08
US09/699,295 US6828431B1 (en) 1999-04-09 2000-10-26 Compositions and methods for the therapy and diagnosis of breast cancer
US09/810,936 US20020068285A1 (en) 1996-01-11 2001-03-16 Compositions and methods for the therapy and diagnosis of breast cancer
PCT/US2001/016776 WO2001090152A2 (en) 2000-05-24 2001-05-22 Compositions and methods for the therapy and diagnosis of breast cancer

Publications (1)

Publication Number Publication Date
MXPA02011563A true MXPA02011563A (es) 2003-06-06

Family

ID=27504920

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02011563A MXPA02011563A (es) 2000-05-24 2001-05-22 Composicionesy metodos para la terapia y diagnostico de cancer de seno.

Country Status (15)

Country Link
US (1) US20020068285A1 (es)
EP (2) EP1283885A2 (es)
JP (1) JP2004508812A (es)
KR (1) KR20030028474A (es)
CN (1) CN1443239A (es)
AU (1) AU2001264893A1 (es)
BR (1) BR0111024A (es)
CA (1) CA2409299A1 (es)
CZ (1) CZ20024213A3 (es)
HU (1) HUP0302566A2 (es)
IL (1) IL152847A0 (es)
MX (1) MXPA02011563A (es)
NO (1) NO20025594L (es)
PL (1) PL366066A1 (es)
WO (1) WO2001090152A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030125536A1 (en) * 1996-01-11 2003-07-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US7241876B2 (en) * 1996-01-11 2007-07-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6656480B2 (en) * 1996-01-11 2003-12-02 Corixa Corporation Compositions and methods for the treatment and diagnosis of breast cancer
ATE354663T1 (de) * 1999-10-07 2007-03-15 Corixa Corp Eine mycobacterium tuberculosis kodierende sequenz zur expression von heterologen proteinen
ATE442866T1 (de) 2000-06-20 2009-10-15 Corixa Corp Fusionsproteine aus mycobakterium tuberculosis
AU2003243151A1 (en) 2002-08-16 2004-03-03 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
WO2005080436A2 (en) * 2004-02-18 2005-09-01 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Antibodies that bind pote and uses thereof
KR100763902B1 (ko) * 2004-02-20 2007-10-05 삼성전자주식회사 유방암 특이적 단백질, 그를 코딩하는 유전자, 및 상기단백질 또는 유전자를 이용한 유방암의 진단 방법
CN101962405A (zh) * 2010-09-30 2011-02-02 南开大学 一种人源乳腺癌抗原及其抗体
US11993790B2 (en) * 2017-10-03 2024-05-28 Prevail Therapeutics, Inc. Gene therapies for lysosomal disorders
CN110132896A (zh) * 2019-05-06 2019-08-16 山西大学 一种快速检测血清中乳腺癌标志物的微型光纤生物传感器

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997025431A1 (en) * 1996-01-10 1997-07-17 Corixa Corporation Compositions and methods for the treatment and diagnosis of cancer
US20030125536A1 (en) * 1996-01-11 2003-07-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
EP0874902A2 (en) * 1996-01-11 1998-11-04 Corixa Corporation Compositions and methods for the treatment and diagnosis of breast cancer
US6225054B1 (en) * 1996-01-11 2001-05-01 Corixa Corporation Compositions and methods for the treatment and diagnosis of breast cancer
ZA982968B (en) * 1997-04-09 1998-10-27 Corixa Corp Compositions and methods for the treatment and diagnosis of breast cancer
MXPA01010186A (es) * 1999-04-09 2004-08-12 Corixa Corp Composiciones y metodos para el tratamiento y diagnostico de cancer de mama.

Also Published As

Publication number Publication date
JP2004508812A (ja) 2004-03-25
AU2001264893A1 (en) 2001-12-03
NO20025594D0 (no) 2002-11-21
BR0111024A (pt) 2004-06-22
EP1283885A2 (en) 2003-02-19
WO2001090152A2 (en) 2001-11-29
IL152847A0 (en) 2003-06-24
NO20025594L (no) 2003-01-21
WO2001090152A3 (en) 2002-06-20
US20020068285A1 (en) 2002-06-06
KR20030028474A (ko) 2003-04-08
EP1696028A3 (en) 2006-12-27
HUP0302566A2 (hu) 2003-10-28
PL366066A1 (pl) 2005-01-24
CZ20024213A3 (cs) 2003-09-17
CA2409299A1 (en) 2001-11-29
EP1696028A2 (en) 2006-08-30
CN1443239A (zh) 2003-09-17

Similar Documents

Publication Publication Date Title
MXPA03001634A (es) Polipeptido tumoral cripto.
MXPA03001389A (es) Composiciones y metodos para la terapia y diagnostico de malignidades asociadas con her-2/neu.
AR031250A1 (es) Composiciones y metodos para la terapia y el diagnostico del cancer de pulmon
PH12019502528A1 (en) Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
AR032743A1 (es) Composiciones y metodos para la terapia y el diagnostico de cancer de pulmon
BR0107643A (pt) Composições e processos para a terapia e diagnóstico de c ncer de próstata
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
BR0110091A (pt) Composições e processos para terapia e diagnóstico de câncer de mama
DE60332355D1 (de) Hla-a24-restringiertes krebsantigenpeptid
WO2001092581A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
SI1472541T1 (sl) Prikazovalni agensi in postopek prikazovanja naaladase ali psma
WO2002092001A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
MXPA02011563A (es) Composicionesy metodos para la terapia y diagnostico de cancer de seno.
BR9808509A (pt) Composições e métodos para o tratamento e diagnóstico do câncer de mama
ZA202209988B (en) In vivo tissue engineering devices, methods and regenerative and cellular medicine employing scaffolds made of absorbable material
WO2003037267A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2003013431A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
CY1111522T1 (el) 84p2a9: ειδικη σε προστατη και ορχεις πρωτεϊνη που εκφραζεται σε υψηλο βαθμο στον προστατικο καρκινο
WO2005051990A3 (en) Polynucleotides overexpressed in breast cancer cells, compositions and methods for the therapy and diagnosis of breast cancer
AU2001233917A1 (en) Bcmp-7 as marker for diagnosis of breast cancer
AR029540A1 (es) COMPOSICIONES Y METODOS PARA EL DIAGNoSTICO Y LA TERAPIA DE CA NCER DE PULMoN
DE60326931D1 (de) In kanzerösen mammazellen differentiell exprimierte genprodukte und ihre verwendungsverfahren
WO2002062203A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
AR029547A1 (es) Composiciones y metodos para la terapia y el diagnostico de cancer de pulmon
ATE435284T1 (de) Zusammensetzungen und verfahren zur therapie und diagnose von lungenkrebs